858 results about "L1" patented technology

The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.

The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof.

The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof.

The invention provides a method of cloning a reproductive and respiratory syndrome resisting pig. The method comprises the following steps: transferring CRISPR / Cas9 targeting vectors and CD163 gene homologous recombination modification vectors into fibroblasts of a pig to obtain positive clone cells, wherein the seventh exon of the endogenous CD163 gene in the positive clone cells of the pig is replaced by the tenth exon of the CD163-L1 gene of human, so that the positive clone cells are incapable of mediating PRRSV invading; obtaining a clone embryo by adopting a somatic cell nucleus transfer technology by taking positive cells as nucleus transfer donor cells and oocytes as nucleus transfer recipient cells; and transferring the clone embryo into the uterus of the pig, and impregnating to obtain a cloned pig. The method provided by the invention is low in cost, the time of obtaining the homozygous pig is shortened greatly, the expression of the CD163 gene is not affected by gene editing, and a foundation is laid for the research into the gene function of large animals and the establishment of disease models on the basis of CRISPR / Cas9 mediated homologous recombination.

The invention relates to fusion protein containing a fluorescent protein fragment and an application of the fusion protein. Specifically, the invention provides the fusion protein, and the fusion protein has a structure as shown in (P1-L1)s-A1-(X)n-A2-(L2-P2)t. (X)n or A1-(X)n in the fusion protein can promote the folding and expression of fusion target peptide, improve the solubility of the fusion protein and reduce the intermolecular interaction of the fusion protein, so that the fusion target peptide can be folded under the high concentration with commercial significance. (X)n or A1-(X)n inthe fusion protein can be digested into a plurality of oligopeptides of which the lengths are far less than the length of the target peptide, so that the separation of the oligopeptides from the target peptide is better facilitated, and the purification of the target peptide is more convenient.

The invention relates to a truncated human papillomavirus type 16 L1 protein, virus-like particles composed of the protein, a vaccine containing the virus-like particles, and an application thereof in preventing cervical cancer.